Journal Article
. 2019 Aug;9().
doi: 10.3389/fonc.2019.00667.

Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer

Mi Jeong Kwon 1 Jeong Eon Lee 2 Joon Jeong 3 Sang Uk Woo 4 Jinil Han 5 Byeong-Il Kang 5 Jee-Eun Kim 5 Youngho Moon 5 Sae Byul Lee 6 Seonghoon Lee 4 Yoon-La Choi 2 Youngmi Kwon 7 Kyoung Song 8 Gyungyub Gong 9 Young Kee Shin 10 
  • PMID: 31404265
  •     34 References
  •     2 citations


Introduction: The GenesWell Breast Cancer Test (BCT) is a recently developed multigene assay that predicts the risk of distant recurrence in patients with early breast cancer. Here, we analyzed the concordance of the BCT score with the Oncotype DX recurrence score (RS) for risk stratification in Asian patients with pN0-N1, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Methods: Formalin-fixed, paraffin-embedded breast cancer tissues previously analyzed using the Oncotype DX test were assessed using the GenesWell BCT test. The risk stratification by the two tests was then compared. Results: A total of 771 patients from five institutions in Korea were analyzed. According to the BCT score, 527 (68.4%) patients were classified as low risk, and 244 (31.6%) as high risk. Meanwhile, 134 (17.4%), 516 (66.9%), and 121 (15.7%) patients were categorized into the low-, intermediate-, and high-risk groups, respectively, according to the RS ranges used in the TAILORx. The BCT high-risk group was significantly associated with advanced lymph node status, whereas no association between RS risk groups and nodal status was observed. The concordance between the two risk stratification methods in the overall population was 71.9% when the RS low-risk, and intermediate-risk groups were combined into one group. However, poor concordance was observed in patients aged ≤50 years and in those with lymph node-positive breast cancer. Conclusions: The concordance between the BCT score and RS was low in women aged ≤50 years or with lymph node-positive breast cancer. Further studies are necessary to identify more accurate tests for predicting prognosis and chemotherapy benefit in this subpopulation.

Keywords: Asian population; GenesWell BCT score; concordance; early breast cancer; oncotype DX recurrence score; risk classification.

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.
J M Harvey, G M Clark, C K Osborne, D C Allred.
J Clin Oncol, 1999 May 20; 17(5). PMID: 10334533
Highly Cited.
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
Prognostic and predictive factors in early-stage breast cancer.
Mary Cianfrocca, Lori J Goldstein.
Oncologist, 2004 Nov 25; 9(6). PMID: 15561805
Highly Cited. Review.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Global trends in breast cancer incidence and mortality 1973-1997.
Michelle D Althuis, Jaclyn M Dozier, +2 authors, Louise A Brinton.
Int J Epidemiol, 2005 Mar 02; 34(2). PMID: 15737977
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Development of the 21-gene assay and its application in clinical practice and clinical trials.
Joseph A Sparano, Soonmyung Paik.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258979
Highly Cited. Review.
Supervised risk predictor of breast cancer based on intrinsic subtypes.
Joel S Parker, Michael Mullins, +17 authors, Philip S Bernard.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204204    Free PMC article.
Highly Cited.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Recent trends and patterns in breast cancer incidence among Eastern and Southeastern Asian women.
Hai-Rim Shin, Clementine Joubert, +16 authors, Philippe Autier.
Cancer Causes Control, 2010 Jun 19; 21(11). PMID: 20559704
Is breast cancer the same disease in Asian and Western countries?
Stanley P L Leong, Zhen-Zhou Shen, +7 authors, William D Foulkes.
World J Surg, 2010 Jul 08; 34(10). PMID: 20607258    Free PMC article.
Highly Cited.
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.
Torsten O Nielsen, Joel S Parker, +12 authors, Matthew J Ellis.
Clin Cancer Res, 2010 Sep 15; 16(21). PMID: 20837693    Free PMC article.
Highly Cited.
Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival.
Yoon-La Choi, Ensel Oh, +12 authors, Young Kee Shin.
BMC Cancer, 2010 Sep 24; 10. PMID: 20860845    Free PMC article.
Invasive breast cancer incidence trends by detailed race/ethnicity and age.
Lihua Liu, Juanjuan Zhang, +2 authors, Dennis Deapen.
Int J Cancer, 2011 Feb 26; 130(2). PMID: 21351091    Free PMC article.
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Martin Filipits, Margaretha Rudas, +25 authors, EP Investigators.
Clin Cancer Res, 2011 Aug 03; 17(18). PMID: 21807638
Highly Cited.
Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer.
Zsuzsanna Varga, Peter Sinn, +6 authors, Holger Moch.
PLoS One, 2013 Mar 19; 8(3). PMID: 23505515    Free PMC article.
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Mitch Dowsett, Ivana Sestak, +7 authors, Jack Cuzick.
J Clin Oncol, 2013 Jul 03; 31(22). PMID: 23816962
Highly Cited.
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C Wolff, M Elizabeth H Hammond, +19 authors, College of American Pathologists.
Arch Pathol Lab Med, 2013 Oct 09; 138(2). PMID: 24099077    Free PMC article.
Highly Cited.
Multigene prognostic tests in breast cancer: past, present, future.
Balázs Győrffy, Christos Hatzis, +3 authors, Lajos Pusztai.
Breast Cancer Res, 2015 Apr 08; 17. PMID: 25848861    Free PMC article.
Highly Cited. Review.
Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
A S Coates, E P Winer, +6 authors, Panel Members.
Ann Oncol, 2015 May 06; 26(8). PMID: 25939896    Free PMC article.
Highly Cited.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Lyndsay N Harris, Nofisat Ismaila, +11 authors, American Society of Clinical Oncology.
J Clin Oncol, 2016 Feb 10; 34(10). PMID: 26858339    Free PMC article.
Highly Cited. Review.
The Basic Facts of Korean Breast Cancer in 2013: Results of a Nationwide Survey and Breast Cancer Registry Database.
Sun Young Min, Zisun Kim, +4 authors, Korean Breast Cancer Society Consortium.
J Breast Cancer, 2016 Apr 12; 19(1). PMID: 27066090    Free PMC article.
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
Richard Buus, Ivana Sestak, +7 authors, Mitch Dowsett.
J Natl Cancer Inst, 2016 Jul 13; 108(11). PMID: 27400969    Free PMC article.
Highly Cited.
Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Armando E Giuliano, James L Connolly, +6 authors, Gabriel N Hortobagyi.
CA Cancer J Clin, 2017 Mar 16; 67(4). PMID: 28294295
Highly Cited.
A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer.
Gyungyub Gong, Mi Jeong Kwon, +15 authors, Young Kee Shin.
Sci Rep, 2017 Mar 30; 7. PMID: 28350001    Free PMC article.
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Ivana Sestak, Richard Buus, +9 authors, Mitch Dowsett.
JAMA Oncol, 2018 Feb 17; 4(4). PMID: 29450494    Free PMC article.
Highly Cited.
Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures.
Zhengyan Kan, Ying Ding, +20 authors, Yeon Hee Park.
Nat Commun, 2018 May 02; 9(1). PMID: 29713003    Free PMC article.
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29860917    Free PMC article.
Highly Cited.
BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer.
Mi Jeong Kwon, Sae Byul Lee, +8 authors, Young Kee Shin.
PLoS One, 2018 Nov 22; 13(11). PMID: 30462685    Free PMC article.
Insights Into Breast Cancer in the East vs the West: A Review.
Yoon-Sim Yap, Yen-Shen Lu, +8 authors, Soo-Chin Lee.
JAMA Oncol, 2019 May 17;. PMID: 31095268
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2019 Jun 04; 380(25). PMID: 31157962    Free PMC article.
Highly Cited.
Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial.
Angela Mariotto, Jinani Jayasekerea, +5 authors, Jeanne S Mandelblatt.
J Natl Cancer Inst, 2019 Jun 06; 112(2). PMID: 31165854    Free PMC article.
Tumor-related prognostic factors for breast cancer.
W L Donegan.
CA Cancer J Clin, 1997 Jan 01; 47(1). PMID: 8996077
UBE2C Overexpression Aggravates Patient Outcome by Promoting Estrogen-Dependent/Independent Cell Proliferation in Early Hormone Receptor-Positive and HER2-Negative Breast Cancer.
Yu-Jin Kim, Gyunghwa Lee, +4 authors, Young Kee Shin.
Front Oncol, 2020 Feb 11; 9. PMID: 32039034    Free PMC article.
A new clinical-genomic model to predict 10-year recurrence risk in primary operable breast cancer patients.
Tzu-Ting Huang, Lei Lei, +3 authors, Skye Hung-Chun Cheng.
Sci Rep, 2020 Mar 19; 10(1). PMID: 32184406    Free PMC article.